REGN5381

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

HealthyHealthy VolunteersHeart FailureUncontrolled Hypertension

Phase 1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

CompletedNCT04506645

Regeneron PharmaceuticalsHealthy

Start: 2020-09-01End: 2022-12-14Updated: 2022-12-20

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

CompletedNCT05291546

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2022-04-13End: 2024-04-02Updated: 2024-04-15

Phase 2

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

CompletedNCT05353166

Regeneron PharmaceuticalsHeart Failure

Start: 2022-06-30End: 2025-06-02Updated: 2025-06-11

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

TerminatedNCT06237309

Regeneron PharmaceuticalsHeart Failure

Start: 2024-04-11End: 2025-12-29Updated: 2026-01-14

REGN5381 in Adult Participants With Uncontrolled Hypertension

TerminatedNCT06833190

Regeneron PharmaceuticalsUncontrolled Hypertension

Start: 2025-04-16End: 2025-10-15Updated: 2025-10-23

Related Papers

Abstract 4364397: Safety and Tolerability of REGN5381, a Monoclonal Antibody Agonist of NPR1 in Patients With Heart Failure With Reduced Ejection Fraction

Circulation2025-11-03

Abstract 13840: Safety Outcomes From a First-in-Human Study of a Novel Investigational Monoclonal Antibody, REGN5381, an Agonist to the Natriuretic Peptide Receptor 1

Circulation2023-11-06